Vertaisarvioitu alkuperäisartikkeli tai data-artikkeli tieteellisessä aikakauslehdessä (A1)

Cost-effective survival prediction for patients with advanced prostate cancer using clinical trial and real-world hospital registry datasets




Julkaisun tekijät: Mika Murtojärvi, Anni S. Halkola, Antti Airola, Teemu D. Laajala, Tuomas Mirtti, Tero Aittokallio, Tapio Pahikkala

Kustantaja: Elsevier Ireland Ltd

Julkaisuvuosi: 2020

Journal: International Journal of Medical Informatics

Lehden akronyymi: INT J MED INFORM

Volyymi: 133

Sivujen määrä: 8

ISSN: 1386-5056

eISSN: 1872-8243

DOI: http://dx.doi.org/10.1016/j.ijmedinf.2019.104014

Verkko-osoite: http://www.sciencedirect.com/science/article/pii/S1386505618311857

Rinnakkaistallenteen osoite: https://research.utu.fi/converis/portal/detail/Publication/43869141


Tiivistelmä
Introduction

Predictive survival modeling offers systematic tools for clinical decision-making and individualized tailoring of treatment strategies to improve patient outcomes while reducing overall healthcare costs. In 2015, a number of machine learning and statistical models were benchmarked in the DREAM 9.5 Prostate Cancer Challenge, based on open clinical trial data for metastatic castration resistant prostate cancer (mCRPC). However, applying these models into clinical practice poses a practical challenge due to the inclusion of a large number of model variables, some of which are not routinely monitored or are expensive to measure.

Objectives

To develop cost-specified variable selection algorithms for constructing cost-effective prognostic models of overall survival that still preserve sufficient model performance for clinical decision making.

Methods

Penalized Cox regression models were used for the survival prediction. For the variable selection, we implemented two algorithms: (i) LASSO regularization approach; and (ii) a greedy cost-specified variable selection algorithm. The models were compared in three cohorts of mCRPC patients from randomized clinical trials (RCT), as well as in a real-world cohort (RWC) of advanced prostate cancer patients treated at the Turku University Hospital. Hospital laboratory expenses were utilized as a reference for computing the costs of introducing new variables into the models.

Results

Compared to measuring the full set of clinical variables, economic costs could be reduced by half without a significant loss of model performance. The greedy algorithm outperformed the LASSO-based variable selection with the lowest tested budgets. The overall top performance was higher with the LASSO algorithm.

Conclusion

The cost-specified variable selection offers significant budget optimization capability for the real-world survival prediction without compromising the predictive power of the model.


Ladattava julkaisu

This is an electronic reprint of the original article.
This reprint may differ from the original in pagination and typographic detail. Please cite the original version.




Last updated on 2022-07-04 at 18:37